Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE versus CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY.
AZELASTINE HYDROCHLORIDE vs CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine hydrochloride is a phthalazinone derivative that exerts its effect by competitively inhibiting histamine at the H1 receptor site. It also stabilizes mast cells, reducing the release of inflammatory mediators such as histamine, leukotrienes, and cytokines. This dual action provides both antihistaminic and anti-inflammatory effects.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors. It inhibits the H1 receptor-mediated effects of histamine, reducing symptoms such as pruritus, sneezing, rhinorrhea, and urticaria. It also decreases eosinophil chemotaxis and adhesion molecule expression.
1 spray (137 mcg) per nostril twice daily; ophthalmic: 1 drop in affected eye(s) twice daily.
5-10 mg orally once daily; max 10 mg/day. For children's formulation, typical adult dose applies to patients >12 years.
None Documented
None Documented
Terminal elimination half-life is approximately 22 hours (range 20–25 hours) following oral administration, supporting twice-daily dosing. For ophthalmic and intranasal routes, systemic half-life is similar due to absorption.
Approximately 8.3 hours (range 6–10 hours) in healthy adults; prolonged in renal impairment (e.g., up to 20 hours).
Approximately 75% of the dose is excreted in feces as unchanged drug and metabolites; about 25% is excreted renally, with less than 10% as unchanged drug.
Renal: ~60% unchanged; fecal: ~10%; minor biliary elimination.
Category C
Category A/B
Antihistamine
Antihistamine